Summit Wealth Group, LLC Esperion Therapeutics, Inc. Transaction History
Summit Wealth Group, LLC
- $342 Million
- Q1 2025
A detailed history of Summit Wealth Group, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Summit Wealth Group, LLC holds 293,000 shares of ESPR stock, worth $307,650. This represents 0.12% of its overall portfolio holdings.
Number of Shares
293,000
Previous 157,000
86.62%
Holding current value
$307,650
Previous $345,000
22.32%
% of portfolio
0.12%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding ESPR
# of Institutions
207Shares Held
128MCall Options Held
1.78MPut Options Held
1.27M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$25.7 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$14.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$12.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$10.4 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$6.62 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $69.9M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...